Dr. Spreafico's full-time academic practice and her research focus on early drug development and phase I clinical trials, with disease-specific interests in melanoma, skin and head and neck cancers. Nationally and Internationally, Dr. Spreafico collaborates with major Institutions including Canadian Cancer Trials Group and the US NCI Cancer Therapy Evaluation Program. She is the Principal Investigator of numerous early phase, first-in-human and first-in-class trials and investigator-initiated biomarker-driven studies for which she holds large-scale peer review funding including the Canadian Cancer Society and Canadian Institutes of Health Research. She is the recipient of several national and international awards and, in the last five years, has published >50 peer-reviewed publications in widely cited journals.